Five years after Danimer Scientific came under scrutiny over its biodegradability claims, the dismissal of a major securities lawsuit raises questions about the legal and financial pressures faced by the American bioplastics producer.
From promising technology to public controversy
Danimer Scientific was once among the most prominent American companies developing polyhydroxyalkanoates (PHA), a family of biodegradable polymers presented as potential alternatives to conventional plastics. The company attracted investor interest through its Nodax technology and ambitions to expand commercial production.
That trajectory changed dramatically in 2021. In March, The Wall Street Journal questioned claims about Nodax’s biodegradability, particularly in marine environments. The reporting drew attention to the distinction between biodegradation under specific conditions and broader assertions about how quickly finished products disappear in nature. Danimer defended its technology and the research behind its claims. The controversy soon extended beyond polymer science.
Short sellers enter the picture
On April 22, 2021, Spruce Point Capital Management publicly challenged Danimer, raising questions about its operations, production capacity, governance and financial projections. Spruce Point disclosed a short position, meaning it stood to benefit financially from a decline in Danimer’s share price. It published additional criticism in subsequent reports.
In September 2021, Muddy Waters Research issued another critical assessment of Danimer’s commercial prospects, customer relationships and ability to scale production. Muddy Waters likewise disclosed a short position. Danimer rejected the allegations and defended its business strategy.
Shareholder litigation and its outcome
Several American law firms announced investigations into potential securities claims, and a federal shareholder lawsuit was filed in May 2021. The allegations included claims that Danimer had overstated aspects of its operations and Nodax’s biodegradability. The related cases were consolidated.
In October 2023, the federal district court dismissed the consolidated securities complaint with prejudice. The U.S. Court of Appeals subsequently upheld the dismissal in 2024.
In plain language, the principal consolidated federal securities lawsuit failed. The ruling did not establish that every Danimer statement was scientifically or commercially correct. Criticism of Danimer and a successful securities-fraud claim are not the same thing.
Bankruptcy in 2025
Danimer subsequently confronted substantial financial and operational difficulties. In March 2025 it filed for Chapter 11 bankruptcy protection, marking a dramatic reversal for a business once promoted as a pioneer of biodegradable plastics.
How much earlier negative publicity, activist short selling and litigation contributed to Danimer’s ultimate difficulties remains an open question. Financing constraints, production economics, commercial performance and the costs of scaling PHA technology must also be examined. A sequence of events is not, by itself, proof of causation.
The Bio-on parallel
Danimer’s experience invites comparison with Italian PHA developer Bio-on. In July 2019, activist short seller Quintessential Capital Management published a report alleging serious problems at Bio-on, which disputed the claims. The company subsequently suffered a financial and judicial crisis.
The cases are not identical: the allegations, finances, legal proceedings and commercial circumstances differed. Nevertheless, both companies developed PHA materials, attracted activist short-selling campaigns and eventually experienced corporate collapse. Does that reveal a particular vulnerability of capital-intensive emerging-materials companies, or mostly a superficial similarity? No evidence presented here establishes a coordinated campaign connecting the two cases.
Were the consequences proportionate?
Short selling, investigative journalism and shareholder litigation can serve legitimate accountability functions. Claims about biodegradability deserve scientific scrutiny, especially when they shape consumer and investor expectations. But the cumulative effects of negative publicity, short-selling reports and legal proceedings on a company’s reputation, access to financing and ability to operate merit examination too.
How should those pressures be assessed when a major securities action is later dismissed? And how did the executives and employees living through those events experience them?
Danimer Scientific’s story is not reducible to a simple narrative of technological failure or proven misconduct. Nor does the litigation’s dismissal demonstrate that short sellers caused the company’s bankruptcy. Five years after the controversy began, the record deserves reassessment through court decisions, business evidence and the personal perspectives of those involved.
